Abstract YO8
Case summary
Carcinosarcoma of the breast is an aggressive, malignant biphasic neoplasm. It is comprised of carcinomatous and sarcomatous elements and accounts for 0.08–0.2% of all breast malignancies. Due to the rarity of this disease, it remains poorly understood and infrequently reported. Here we present a case of a 38 year old Filipino woman with a 2 month history of mass in her left breast. Progressive enlargement of the mass warranted excisional biopsy and revealed high grade carcinoma. Metastatic work up were unremarkable. Thus, the patient underwent modified radical mastectomy. Histopathology revealed metaplastic carcinoma, carcinosarcoma type with background of ductal carcinoma in-situ, nuclear grade 1 with no definite lymphovascular space invasion. All 12 lymph nodes were negative for tumor but nipple was positive for tumor. Immunohistochemistry report revealed positive for ER, PR and negative for HER2/Neu overexpression. Furthermore, tumor cells were positive for pancytokeratin in carcinomatous areas and vimentin in sarcomatous areas. The patient is receiving hormonal therapy and remains to be asymptomatic and on close surveillance.
A multi-disciplinary approach with an accurate diagnosis are essential to optimally tailor potentially effective treatment options in this kind of patients. To date, there is no standardized treatment protocol for the management of carcinosarcoma of the breast. Long-term follow-up is important because of the increased likelihood of local recurrence and metastasis.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
220P - An outcome analysis of robotassisted radical nephroureterectomy with extended template lymphadenectomy for upper tract urothelial carcinoma
Presenter: Ashwin Tamhankar
Session: Poster display session
Resources:
Abstract
221P - Comparative analysis of first-line immune checkpoint inhibitor versus carboplatin-based chemotherapy for cisplatin-ineligible metastatic urothelial carcinoma: A multicenter, retrospective real-world evidence
Presenter: Hsiang‐Lan Lai
Session: Poster display session
Resources:
Abstract
222P - Does tumor grade really improve the prognostic ability of the staging system for men with penile cancer: A SEER database analysis
Presenter: Ravi Kanodia
Session: Poster display session
Resources:
Abstract
223TiP - EV-301: A phase III trial in progress evaluating enfortumab vedotin versus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma
Presenter: Daniel Petrylak
Session: Poster display session
Resources:
Abstract
230P - Olaparib maintenance therapy in patients (pts) with a BRCA1 and/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 China cohort
Presenter: Lingying Wu
Session: Poster display session
Resources:
Abstract
231P - Cost-effectiveness of olaparib vs routine surveillance in the maintenance setting for patients with BRCA-mutated advanced ovarian cancer after response to first-line platinum-based chemotherapy in Singapore
Presenter: David SP Tan
Session: Poster display session
Resources:
Abstract
233P - Incorporation of correlative studies in ovarian cancers in the era of precision medicine: Assessment of accountability and utility
Presenter: Nadia Hitchen
Session: Poster display session
Resources:
Abstract
234P - Implementation of mainstream BRCA testing in epithelial ovarian cancer in a tertiary centre
Presenter: Edbert Wong
Session: Poster display session
Resources:
Abstract
235P - The efficacy of radiation therapy in ovarian carcinoma: A propensity score analysis of a population-based study
Presenter: Jian-Guo Zhou
Session: Poster display session
Resources:
Abstract
236P - Front-line maintenance therapy for platinum-sensitive ovarian cancer: What’s next PARP inhibitors?
Presenter: Han Gong
Session: Poster display session
Resources:
Abstract